Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Soleno Therapeutics, Inc. (NASDAQ:SLNO) has a consensus Buy rating, as all 13 analysts covering the stock have assigned a ‘Buy’ or equivalent rating. With a median price of $110, the stock boasts an upside potential of around 114%. On November 5, Kristen Kluska, an analyst at Cantor Fitzgerald, reiterated a ‘Buy’ rating on Soleno Therapeutics, Inc. (SLNO), with a price target of $123. S ...

Core Insights - Soleno Therapeutics Inc. (NASDAQ: SLNO) experienced a significant decline of 26.59% in stock price, closing at $46.87, marking the fifth consecutive day of losses as investors anticipated strong earnings for Q3 [1][3] - The company reported a net income of $26 million for the third quarter, a 134% improvement from a net loss of $76.6 million in the same period last year, with revenues reaching $66 million [2][3] Company Performance - The strong Q3 results are attributed to increased awareness of the efficacy and safety of Vykat XR, the first and only FDA-approved drug for hyperphagia, particularly within the Prader-Willi Syndrome (PWS) community [3][4] - Vykat XR is positioned as a critical treatment option for patients aged 4 years and older suffering from hyperphagia, addressing a complex patient population with serious co-morbidities [4]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as a promising healthcare stock with significant upside potential, particularly following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $125 [1]. Group 1: Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, specifically targeting neurobehavioral and metabolic disorders [3]. - The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet designed to treat Prader-Willi Syndrome (PWS) [3]. Group 2: Recent Developments - Goldman Sachs anticipates that Soleno Therapeutics' Vykat XR will become a foundational treatment for Prader-Willi syndrome, with expectations for the drug to evolve into a blockbuster franchise [2]. - The recent pullback in the stock price is viewed as an attractive entry point for investors looking to capitalize on the company's potential [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The law firm is reaching out to investors who purchased or acquired Soleno shares and suffered losses, encouraging them to discuss their legal rights [1][2]. - There is no cost or obligation for investors to contact the firm regarding these claims [2]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3]. Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The law firm is reaching out to Soleno stockholders who have suffered losses, encouraging them to discuss their legal rights and options [1][2] - There is no cost or obligation for stockholders to inquire about their rights or the ongoing investigation [2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3] Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5]

Core Insights - Acadia Pharmaceuticals' shares fell by 9.9% following disappointing results from a late-stage study of ACP-101 for hyperphagia in Prader-Willi syndrome [1][3] Study Results - The phase III COMPASS PWS study evaluated a 3.2 mg thrice-daily dose of ACP-101 in 175 participants aged 5 to 30 years [2] - ACP-101 did not achieve a statistically significant benefit over placebo on the primary endpoint and failed to show separation from placebo on secondary endpoints [3] Financial Performance - Despite the setback, Acadia's shares have gained 15.8% year-to-date, outperforming the industry growth of 3.6% [3] - Nuplazid and Daybue sales rose significantly in the first half of 2025, contributing to revenue growth [5] Marketed Products - Nuplazid generated $328.2 million in sales in H1 2025, a 14% increase year-over-year, benefiting from volume growth [7] - Daybue recorded $180.7 million in sales in H1 2025, up 13% year-over-year, indicating strong growth in new patient starts and treatment persistence [8] Pipeline Development - Acadia is focused on developing its pipeline candidates to reduce reliance on Nuplazid for revenue [9] - A regulatory filing for trofinetide for Rett syndrome is under review in the EU, with approval expected in Q1 2026 [9] - ACP-204 is being developed for Alzheimer's disease psychosis, with enrollment completion anticipated in Q1 2026 and top-line data expected mid-2026 [10] Competitive Landscape - Soleno Therapeutics' Vykat XR has gained a stronger market position following Acadia's decision to discontinue ACP-101, as it is now the only FDA-approved treatment for hyperphagia in PWS [12][13]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR, which led to a significant drop in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Soleno Therapeutics, Inc. and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Scorpion Capital that criticized Soleno's only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [3]. Group 2: Stock Price Impact - Following the release of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, which is a decline of 7.41%, closing at $71.63 per share on the same day [3]. Group 3: Company Background - Soleno Therapeutics, Inc. is a company that has been under scrutiny due to concerns regarding its product and business practices, which may affect investor confidence and market performance [1][3].

Core Insights - Acadia Pharmaceuticals Inc. released topline results from its Phase 3 COMPASS PWS trial, which evaluated the efficacy and safety of intranasal carbetocin in patients with hyperphagia in Prader-Willi syndrome (PWS) [1][3]. Company Performance - The Phase 3 trial did not show a statistically significant improvement of intranasal carbetocin over placebo on the primary endpoint, which was the change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) [3]. - The safety profile of intranasal carbetocin was consistent with previous trials, showing a low rate of adverse events [4]. - Despite the trial results, Acadia is projected to generate over $1 billion in net sales from two approved products by 2025 and has a robust pipeline with eight disclosed and multiple undisclosed programs [5]. Market Reaction - Following the trial results, ACAD stock experienced a decline of 11.02%, trading at $21 during the premarket session [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Core Insights - Shares of Soleno Therapeutics (NASDAQ:SLNO) experienced a decline following the report of a death of a 17-year-old male patient who was treated with the company's recently launched rare disease therapy, Vykat XR [3] Company Summary - Soleno Therapeutics is a biotech company based in Redwood City, California, which recently launched a therapy for rare diseases [3]